Moreover, semaglutide improved surrogate outcomes such as NT-proBNP levels and NYHA class in patients with obesity-related HFpEF, as shown by Petrie et al. [13] and Schou et al. [6]. The gene discussed is NPPB; the disease is obesity disorder.